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ABSTRACT
Objective Post- randomisation exclusions in randomised 
controlled trials are common and may include participants 
identified as not meeting trial eligibility criteria after 
randomisation. We report how a decision might be 
reached and reported on, to include or exclude these 
participants. We illustrate using a motivating scenario 
from the BREATHE trial (Trial registration  ClinicalTrials. gov, 
NCT02426112) evaluating azithromycin for the treatment 
of chronic lung disease in people aged 6–19 years with HIV 
in Zimbabwe and Malawi.
Key points Including all enrolled and randomised 
participants in the primary analysis of a trial ensures 
an unbiased estimate of the intervention effect using 
intention- to- treat principles, and minimises the effects 
of confounding through balanced allocation to trial arm. 
Ineligible participants are sometimes enrolled, due to 
measurement or human error. Of 347 participants enrolled 
into the BREATHE trial, 11 (3.2%) were subsequently 
found to be ineligible based on lung function criteria. 
We assumed no safety risk of azithromycin treatment; 
their inclusion in the trial and subsequent analysis of 
the intervention effect therefore mirrors clinical practice. 
Senior trial investigators considered diurnal variations in 
the measurement of lung function, advantages of retaining 
a higher sample size and advice from the Data Safety 
and Monitoring Board and Trial Steering Committee, and 
decided to include these participants in primary analysis. 
We planned and reported analyses including and excluding 
these participants, and in our case the interpretation of 
treatment effect was consistent.
Conclusion The decision, by senior investigators, on 
whether to exclude enrolled participants, should reflect 
issues of safety, treatment efficacy, statistical power and 
measurement error. As long as decisions are made prior 
to finalising the statistical analysis plan for the trial, the 
risk of exclusions creating bias should be minimal. The 
decision taken should be transparently reported and a 
sensitivity analysis can present the opposite decision.
MOTIVATING EXAMPLE
In an individually randomised placebo- 
controlled trial (registered  ClinicalTrials. 
gov, NCT02426112) of the impact of azithro-
mycin on treatment of chronic lung disease 
in children and adolescents born with HIV 
in Zimbabwe and Malawi, one eligibility 
criterion was a measurement cut- off for lung 
function (using forced expiratory volume in 1 
second (FEV1) z- score).
1 2 After enrolment was 
complete, and prior to data analysis, inconsis-
tencies were identified with the FEV1 inclusion 
criteria. Specifically, height (an input variable 
for the reference equations on the European 
Respiratory Society/Global Lung function 
Initiative 2012 spreadsheet to compute the 
FEV1 z- score,
3) measured at screening did not 
always align with height measurements from 
later study visits. A review of practices under-
taken found that in one country, different 
models of stadiometers were used at different 
screening centres resulting in inconsistencies 
in height measurements. It was decided to 
recalculate the z- score using a mean of height 
from two later study visits in that country, and 
in the other country to use a mean height 
from screening and two later study visits (up 
to 2 weeks after randomisation). These recal-
culations meant that 11/347 (3.2%) partici-
pants fell outside the lung function cut- off for 
inclusion into the trial and a debate ensued 
among the trial investigators as to how to 
proceed. The first stage was to unmask these 
participants to the local study physician, 
report this protocol violation to the Data 
Safety and Monitoring Board (DSMB), and 
the Trial Steering Committee (TSC) and to 
the relevant ethics committee(s).
At this stage, 7 of the 11 ineligible partic-
ipants had completed their course of study 
medication and the remaining four partic-
ipants had between 1 and 3 weeks of study 
medication remaining. The trial drug, azith-
romycin, is considered safe,4 so the potential 
for harm in continuing the four participants 
on treatment was considered low. The initial 
suggestion from the investigators was to with-
draw these participants from the trial and 
stop treatment, but the DSMB and TSC 
advised that they should be included as the 
primary analysis, with a sensitivity analysis 
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excluding them. The reason for this was (1) lung func-
tion may vary by time of day,5 so if lung function had 
been retested at a different time even on the same day, 
eligibility may have been different, (2) the low risk of 
treatment- related adverse events and (3) the advantage 
in retaining a greater sample size (original power calcu-
lations required 300 for primary outcome at 12 months). 
Further, a prespecified subgroup analysis was included 
in the statistical analysis plan to investigate effect modi-
fication by baseline FEV1 measurement, and provide esti-
mates of treatment effect at different severities of baseline 
lung function. We also considered the possible adverse 
impact on statistical power if ineligible participants were 
less responsive to azithromycin treatment than eligible 
participants (potentially resulting in greater variability 
of treatment effect). On balance, this was outweighed by 
reasons to include ineligible participants.
STATISTICAL CONSIDERATIONS
The intention- to- treat (ITT) principle underpins the anal-
ysis of randomised controlled trials as a means of obtaining 
balance between arms on potential confounding factors, 
and preventing estimates of the intervention effect from 
being biased.6 7 ITT in its purest form estimate the inter-
vention effect for all enrolled randomised participants, 
based on the initial arm allocation. In practice, the 
trial outcomes may not be measured or analysed for all 
randomised participants and this may impact on the ITT 
principle. One reason for not measuring outcomes in all 
enrolled participants is attrition, causing missing outcome 
data. If outcome data are missing not at random the ITT 
principle can become compromised.8 A second reason, 
which compromises the ITT principle, but is common 
nonetheless,9 is that some randomised participants may 
Table 1 Reasons for and against post- randomisation exclusions
Issue Reason to include Reason to exclude
Clinical scenario     
  Make recommendations of benefit or 
harm (based on trial results) relating to 
a certain patient population
Where there is uncertainty over defining 
patient populations, it would be a 
conservative approach to retain all 
participants.
Retains a defined group of included 
participants meeting inclusion/exclusion 
criteria neatly in which the intervention is 
hypothesised to be the most effective.
  Disease status may be unclear Measurement cut- off may not relate to a 
‘disease’ state and may be arbitrary.
Measurement cut- offs are commonly used to 
indicate disease severity although knowing 
there may be some misclassification.
  Assessment of safety risks There is no safety risk to participants after 
review and therefore treatment and follow- up 
can continue.
Randomisation was mistakenly done, for 
example when found not to be diseased. 
Where safety was compromised the 
participants should cease remaining 
treatment and most likely be excluded from 
analysis.
Statistical analysis     
  Maintain ITT principles, providing an 
unbiased treatment effect
Stays true to ITT principle ensuring balance 
on known and unknown factors between 
arms when all enrolled and randomised 
participants are analysed.
The risk of bias from excluding some 
participants has been shown to be low under 
certain conditions.
  The inclusion criteria are subject to 
measurement error. The relationship 
between the inclusion criteria and 
the primary outcome should be 
considered.
Pragmatically, errors in measurement will 
occur in routine practice. They may have 
been considered eligible at the point of 
enrolment. Include if measurement of 
the primary outcome is not impacted by 
measurement error in the inclusion criteria.
Identification of errors in the measurement of 
disease state and excluding them can prevent 
underestimation of treatment effects.
  Effect on statistical power A larger sample size is retained. If ineligible participants’ responses to 
treatment differ from those for eligible 
participants (eg, less response), the variance 
of the primary outcome may be increased 
meaning there may be more statistical power 
to exclude them.
Integrity and transparency     
  Justifying the decision to include or 
exclude
Post- randomisation exclusions may be 
mistrusted in the scientific community if 
conflicts of interest or the trial sponsor are 
shown to have influenced the decision- 
making.
Post- randomisation exclusions are a common 
approach in the scientific community and will 
be accepted when clearly justified.
*ITT intention- to- treat
 on D
ecem









pen: first published as 10.1136/bm






3Rehman AM, et al. BMJ Open 2020;10:e039546. doi:10.1136/bmjopen-2020-039546
Open access
be excluded from analysis post- randomisation. Reasons 
for such exclusions might be that participants (1) have 
incomplete baseline or outcome data, (2) did not receive 
the intervention allocated or (3) were found to be inel-
igible post- randomisation. In this communication, we 
summarise issues to consider when deciding whether to 
exclude enrolled, but ineligible, participants during the 
analysis of the intervention effect (table 1).
There is conflicting evidence as to whether post- 
randomisation exclusions of enrolled participants 
produce bias.10–13 Bias can be considered a potential issue 
where decisions about exclusions are influenced by the 
trial sponsor or conflicts of interest of the investigators.14
The statistical power of the trial may be affected in 
either direction when ineligible individuals are enrolled 
incorrectly. Including the ineligible enrolled participants 
in analysis will retain a larger sample size, while excluding 
them may increase the variance of the estimated interven-
tion effects (if those ineligible were to respond differently 
to treatment than eligible participants).
The type of inclusion/exclusion criteria must be consid-
ered. For example, in a drug treatment trial providing 
treatment for a certain infection, if it was found post- 
randomisation that an enrolled participant was unin-
fected it is best to exclude that participant from analysis 
and withdraw them immediately from the trial. Decisions 
are less clear if (1) the criteria include a cut- off used for 
inclusion (eg, body mass index), and there is error in the 
measurement of this, or (2) exclusion criteria include 
the presence of a clinical condition for which screening 
tests were not available at enrolment and only become 
apparent during follow- up.
Depending how quickly it became apparent that a 
participant did not meet eligibility criteria, trial outcome 
data may have been collected on ineligible enrolled 
participants and a decision must be made whether to 
include them in primary analysis. If excluded, a ‘modified 
ITT’ may be performed.15–17
REPORTING AND REFLECTION ON MOTIVATING EXAMPLE
The primary outcome was analysed for 308 participants, 11 
of whom were ineligible based on FEV1 inclusion criteria. 
By chance, differences were observed between trial arms 
in age and sex distributions and with HIV- related char-
acteristics. Primary analyses were therefore prespecified, 
prior to unmasking of outcome data, to adjust for site, 
age, sex and HIV viral load. Once- weekly administration 
of azithromycin did not improve lung function measured 
by FEV1 z- score after 48 weeks in ITT analysis (adjusted 
mean difference (aMD) 0.06%, 95% CI −0.10% to 0.21%) 
and in sensitivity analysis excluding those who did not 
meet eligibility criteria (aMD 0.07%, 95% CI −0.08% to 
0.23%).2 The prespecified per- protocol analysis suggested 
weak evidence for an effect of azithromycin, with an aMD 
in z- scores of 0.14 (95% CI −0.02 to 0.29) favouring azith-
romycin. Those not meeting eligibility criteria were more 
likely to be in the azithromycin arm, in Malawi, younger, 
of male sex and have HIV viral suppression (table 2).
The study was powered to detect a 0.32 z- score differ-
ence between trial arms with 300 participants assuming a 
mean z- score of −2.04 (SD 0.82) in the placebo arm. The 
primary outcome was assessed in 308 participants, with a 
mean of −1.95 (SD 0.91) in the placebo arm. Effectively, 









Placebo arm, n (%) 170 (51) 142 (48) 4 (36)
AZM arm, n (%) 166 (49) 155 (52) 7 (64)
Baseline FEV1 z- score, mean (SD) −2.05 (0.72) −2.05 (0.73) −0.67 (0.38)
48- week FEV1 z- score, mean (SD) – −1.95 (0.90) −1.24 (0.84)
Zimbabwe site, n (%) 241 (72) 219 (74) 0 (0)
Malawi site, n (%) 95 (28) 78 (26) 11 (100)
Aged 6–10, n (%) 44 (13) 40 (13) 3 (27)
Aged 11–15, n (%) 152 (45) 135 (45) 6 (55)
Aged 16–19, n (%) 140 (42) 122 (41) 2 (18)
Female sex, n (%) 166 (49) 142 (48) 4 (36)
Male sex, n (%) 170 (51) 155 (52) 7 (64)
Baseline log10 HIV viral load, mean (SD)† 2.79 (1.61) 2.72 (1.59) 2.32 (1.95)
Baseline suppressed HIV viral load (<1000 
copies/mL), n (%)†
187 (56) 171 (58) 7 (64)
*All ineligible randomised participants were analysed for the primary outcome.
†N=2 missing values among eligible participants were imputed in the primary analysis using chained equations.
AZM, azithromycin; FEV1, forced expiratory volume in 1 second.
 on D
ecem









pen: first published as 10.1136/bm






4 Rehman AM, et al. BMJ Open 2020;10:e039546. doi:10.1136/bmjopen-2020-039546
Open access 
with a sample size of 146 in the placebo arm and 162 in 
the azithromycin arm, the study had 80% power to detect 
a 0.29 z- score difference between trial arms; excluding 
ineligible participants gave the same z- score difference.
In practice, the inclusion of ineligible participants did 
not change the interpretation of the trial results, likely 
due to their low numbers and/or because the adjust-
ments used for primary analysis (to account for baseline 
imbalance) were also associated with ineligibility (and 
being assessed for the primary outcome). The study 
remained sufficiently powered. Sensitivity analyses were 
prespecified in a formal statistical analysis plan, shared 
with reviewers and reported in the publication of the 
trial findings for transparency and to maintain research 
integrity.
CONCLUSION
There is not a one- size- fits- all approach to deciding 
on post- randomisation exclusions and in fact, there is 
evidence to suggest that more trials tend to make post- 
randomisation exclusions than do not.9 Consideration 
should be given to safety, assessment of treatment effects, 
statistical power and measurement error (table 1). We 
recommend that the decision is made after a joint discus-
sion among senior trial investigators in conjunction with 
the TSC and DSMB. Others may advise, but the final 
decision falls to the senior investigators of the trial who 
should not be influenced by the trial sponsor or conflicts 
of interest, financial or otherwise. To further reduce bias, 
a decision should be made prior to finalising the statistical 
analysis plan for the trial, and for transparency, reported 
explicitly when publishing the trial results. Justification 
for including or excluding the participants who were 
found not to meet inclusion criteria after randomisation 
should be presented for scrutiny by the scientific commu-
nity and it may be appropriate to consider a sensitivity 
analysis using the opposite decision. The aim of any deci-
sion is to remain as close to ITT principles as possible and 
present an unbiased estimate of the treatment effect.
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